Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Stock

Equities

RICHTER

HU0000123096

Pharmaceuticals

End-of-day quote Budapest S.E. 06:00:00 2024-04-11 pm EDT 5-day change 1st Jan Change
9,390 HUF -0.74% Intraday chart for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. +0.43% +7.31%
Sales 2024 * 836B 2.25B Sales 2025 * 920B 2.48B Capitalization 1,706B 4.6B
Net income 2024 * 223B 601M Net income 2025 * 249B 670M EV / Sales 2024 * 1.88 x
Net cash position 2024 * 136B 367M Net cash position 2025 * 222B 598M EV / Sales 2025 * 1.61 x
P/E ratio 2024 *
7.71 x
P/E ratio 2025 *
6.97 x
Employees 11,603
Yield 2024 *
4.83%
Yield 2025 *
5.68%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart
Gedeon Richter Plc. Proposes Dividend CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Q4 2023 Earnings Call, Feb 29, 2024
Gedeon Richter plc announces Board Changes, Effective 1 March 2024 CI
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million MT
GRANATA BIO Corp announced that it has received $14 million in funding from GV Management Company, LLC, CooperSurgical, Inc., Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Alumni Ventures Group, LLC, Vibe Biotechnology Inc., Amboy Street Ventures and other investors. CI
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China MT
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Q3 2023 Earnings Call, Nov 08, 2023
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for  Commercialisation of RYEQO® CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis CI
GRANATA BIO Corp announced that it expects to receive $15.590561 million in funding from GV Management Company, LLC, CooperSurgical, Inc., Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Alumni Ventures Group, LLC, Vibe Biotechnology Inc., Amboy Street Ventures CI
Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Latest transcript on Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

1 day-0.74%
1 week+0.43%
Current month+1.40%
1 month+0.81%
3 months+1.57%
6 months+7.93%
Current year+7.31%
More quotes
1 week
9 290.00
Extreme 9290
9 490.00
1 month
9 200.00
Extreme 9200
9 525.00
Current year
8 685.00
Extreme 8685
9 965.00
1 year
7 630.00
Extreme 7630
9 965.00
3 years
6 310.00
Extreme 6310
9 965.00
5 years
4 702.00
Extreme 4702
9 965.00
10 years
3 300.00
Extreme 3300
9 965.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 -
Director of Finance/CFO 57 21-12-31
Chief Tech/Sci/R&D Officer 64 83-12-31
Members of the board TitleAgeSince
Director/Board Member 76 69-12-31
Director/Board Member 57 21-04-14
Chairman 88 07-12-31
More insiders
Date Price Change Volume
24-04-15 9,335 -0.59% 115,669
24-04-12 9,390 -0.74% 194,536
24-04-11 9,460 +0.32% 153,287
24-04-10 9,430 +0.32% 197,110
24-04-09 9,400 +0.53% 304,426

End-of-day quote Budapest S.E., April 11, 2024

More quotes
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9,335 HUF
Average target price
11,516 HUF
Spread / Average Target
+23.36%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. RICHTER Stock